McSally Failing Arizona On Spiking Prescription Drug Costs
Martha McSally Is Failing Arizona On Spiking Prescription Drug Costs
Report: “Drug prices in 2019 are surging, with hikes at 5 times inflation”
McSally and the GOP-controlled Senate have refused to take up legislation to lower prescription drug costs
PHOENIX — U.S. Sen. Martha McSally‘s failure to stand up to her party and her pharmaceutical industry backers is costing Arizonans, according to a new report showing that pharmaceutical companies have aggressively jacked up drug prices in 2019.
According to CBS News, “More than 3,400 drugs have boosted their prices in the first six months of 2019, an increase of 17% in the number of drug hikes from a year earlier.”
In May, the House of Representatives passed a bill to “rein in the cost of prescription medicine.” But rather than push her party to take action to hold drug companies accountable for jacking up prices, McSally has adopted an “OK, whatever” philosophy towards Mitch McConnell’s failure to legislate in the Senate.
McSally’s failure to stand up for Arizonans is unsurprising. Over the years, pharmaceutical companies have bought McSally’s loyalty with tens of thousands in corporate PAC money contributions. And it’s similarly no surprise that McSally won’t stand up to her party: Mitch McConnell personally lobbied for McSally’s appointment, so McSally owes him a lot.
Rather than take on drug companies, McSally has instead worked to give her pharmaceutical industry backers a massive tax break. The 2017 GOP tax law gave four large pharmaceutical corporations a $7 billion tax cut, in 2018, alone. And a fifth pharma giant, Eli Lilly, paid zero in corporate income taxes in 2018, under McSally’s law, despite pulling in $598,000,000 in profits.
Martha McSally is failing to be an independent leader for Arizona. And McSally’s refusal to take on her party leadership and the powerful drug companies that fund her campaigns is disqualifying.